Squarepoint Ops LLC Makes New $179,000 Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)

Squarepoint Ops LLC bought a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 46,929 shares of the company's stock, valued at approximately $179,000. Squarepoint Ops LLC owned about 0.61% of Precision BioSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of DTIL. Tang Capital Management LLC grew its stake in shares of Precision BioSciences by 8.0% during the fourth quarter. Tang Capital Management LLC now owns 673,332 shares of the company's stock worth $2,565,000 after purchasing an additional 50,000 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Precision BioSciences by 22.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company's stock valued at $59,000 after acquiring an additional 2,805 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Precision BioSciences by 58.0% during the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company's stock worth $586,000 after acquiring an additional 56,400 shares in the last quarter. Jane Street Group LLC purchased a new stake in Precision BioSciences during the fourth quarter worth approximately $146,000. Finally, Lynx1 Capital Management LP purchased a new stake in Precision BioSciences during the fourth quarter worth approximately $2,919,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Stock Performance

Shares of DTIL traded down $0.04 during midday trading on Thursday, reaching $5.03. 35,622 shares of the stock were exchanged, compared to its average volume of 185,695. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $12.11. The business's 50-day moving average price is $5.01 and its 200 day moving average price is $5.12. The company has a market capitalization of $55.77 million, a price-to-earnings ratio of 83.85 and a beta of 1.48.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $5.00 million. On average, sell-side analysts expect that Precision BioSciences, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Precision BioSciences in a research note on Wednesday, May 21st.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.